Diabesity Rounds

Phase 3 trial reports BMI changes with liraglutide 3.0 mg in children aged 6 to 11

In a 56-week randomised Phase 3 trial of children aged 6 to below 12 years with obesity, liraglutide 3.0 mg reduced mean BMI compared to placebo.

Correction:

17 November 2026: Corrected on 17 November 2026: an earlier version said the registry record gave no confidence intervals or adverse event figures, and that no peer-reviewed paper was available. The record does give both, and the trial (SCALE Kids) has been published. Units were also added to the treatment differences.

At a glance

  • Phase 3 trial enrolled 82 children aged 6 to below 12 years with obesity.
  • Mean relative BMI fell by 6.7% with liraglutide 3.0 mg and rose by 2.1% with placebo at week 56.
  • Treatment difference was -7.40 percentage points in the ANCOVA analysis and -8.26 percentage points in the mixed models analysis.

Key result

Mean BMI fell 6.7% with liraglutide 3.0 mg compared with a 2.1% increase with placebo.

Relative change in Body Mass Index (BMI), 56 weeks

liraglutide 3.0 mg−6.7%
placebo2.1%

82 participants · 56 weeks · p=0.0005

Numbers as reported in the source.

The study

NCT04775082 is a 56-week, double-blind, randomised, placebo-controlled Phase 3 trial sponsored by Novo Nordisk A/S. The trial evaluated the effect and safety of liraglutide 3.0 mg on weight management in children with obesity aged 6 to below 12 years. The trial enrolled 82 participants. Participants were assigned by chance to receive either once-daily liraglutide 3.0 mg or placebo injections. The record notes that liraglutide is a new medicine for children, but it can already be prescribed by doctors to adults with overweight or obesity. In addition to taking the study medicine or placebo, participants had talks with study staff about healthy food choices, how they can be more physically active, and what can be done to help them lose weight. The complete study was planned to last for about 96 weeks (almost 2 years). The protocol involved 18 clinic visits, 10 phone or video calls with study staff, blood samples, 1 test to check the heart, 1 hand X-ray, and participant diaries kept between visits.

What they found

The primary outcome was the relative percentage change in body mass index (BMI) from baseline (week 0) to week 56.

In the liraglutide 3.0 mg group, mean BMI fell by 6.7% (standard deviation 9.6).

In the placebo group, mean BMI rose by 2.1% (standard deviation 6.1).

Statistical analyses showed a statistically significant difference between groups:

  • In the ANCOVA analysis, the treatment difference was -7.40 percentage points (p = 0.0005).
  • In the mixed models analysis, the treatment difference was -8.26 percentage points (p = 0.0003).

The registry record also posts adverse event tables; see the record for the full safety data.

How much weight to give it

This report is based on the results posted on the ClinicalTrials.gov registry record for this trial (SCALE Kids). Total enrolment was 82 participants, and the placebo group was small. Although the study used a double-blind, randomised, placebo-controlled Phase 3 design, these findings reflect the 56-week primary endpoint, whereas the full protocol covers about 96 weeks. Results for the remaining weeks of the protocol are not covered here.

For your clinic

This Phase 3 trial evaluated once-daily liraglutide 3.0 mg alongside lifestyle discussions on healthy food choices and physical activity in children aged 6 to below 12 years with obesity. At week 56, mean relative BMI fell in the liraglutide group and rose in the placebo group, showing a statistically significant treatment difference. The trial record notes that liraglutide is a new medicine for children, but can already be prescribed by doctors to adults with overweight or obesity. The registry record gives the full efficacy and safety tables.

Source

Effect and Safety of Liraglutide 3.0 mg on Weight Management in Children With Obesity Aged 6 to Below 12 Years: 56-week, Double-blind, Randomised, Placebo-controlled Trial

Novo Nordisk A/S. ClinicalTrials.gov results. 16 November 2026

Read the source

Teaching a session? Download this report as a slide (PNG, free to use with credit).

For registered medical practitioners. This report summarises published research and is not advice for individual patients. Read the full paper and current guidelines before changing practice. Found an error? Write to editor@diabesityrounds.com; see our corrections and editorial policy.

More on glp-1 and incretin drugs

Go deeper